Detalhe da pesquisa
1.
Efficacy, rate of tumor response, and safety of a short course (12-24 weeks) of oral vismodegib in various histologic subtypes (infiltrative, nodular, and superficial) of high-risk or locally advanced basal cell carcinoma, in an open-label, prospective case series clinical trial.
J Am Acad Dermatol
; 82(4): 946-954, 2020 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-31836564